诺沃诺迪斯克计划在全球削减9 000个就业机会,以关注肥胖症和糖尿病的治疗。 Novo Nordisk plans to cut 9,000 jobs globally to focus on obesity and diabetes treatments.

丹麦Novo Nordisk制药公司计划在全球削减9 000个就业机会,包括丹麦的5 000个就业机会,以便在市场竞争加剧的情况下,简化业务,加强对肥胖症和糖尿病治疗的关注。 Danish pharmaceutical company Novo Nordisk plans to cut 9,000 jobs globally, including 5,000 in Denmark, to streamline operations and boost focus on obesity and diabetes treatments amid increased market competition. 结构调整的目的是到2026年节省12.5亿美元,用于增长领域的研究和发展。 The restructuring aims to save $1.25 billion by 2026, which will be redirected to research and development in growth areas. 这一行动是在销售增长放缓和竞争激烈,特别是Eli Lilly的竞争加剧之后采取的。 The move follows slowing sales growth and intense competition, particularly from Eli Lilly.